Article ; Online: Pharmacokinetic considerations for angiogenesis inhibitors used to treat hepatocellular carcinoma: an overview.
Expert opinion on drug metabolism & toxicology
2023 Volume 19, Issue 11, Page(s) 785–794
Abstract: Introduction: Hepatocellular carcinoma (HCC) is the fifth malignancy in terms of frequency and the fourth malignancy in terms of cancer-related death worldwide. Systemic therapy of advanced HCC has probably gone through the greatest wave of change in ... ...
Abstract | Introduction: Hepatocellular carcinoma (HCC) is the fifth malignancy in terms of frequency and the fourth malignancy in terms of cancer-related death worldwide. Systemic therapy of advanced HCC has probably gone through the greatest wave of change in the last decade, with the introduction of several anti-angiogenic drugs and immune checkpoint inhibitors, able to significantly improve patients' prognosis. Areas covered: In this review, we summarize the pharmacokinetic characteristic of the antiangiogenic drugs currently approved for the treatment of HCC, from oral tyrosine kinase inhibitors (sorafenib, lenvatinib, regorafenib and cabozantinib) to monoclonal antibodies (bevacizumab and ramucirumab), focusing on the main aspects that differ among compounds from the same class, on factors that can exert an influence on pharmacokinetic parameters and the main issues that could limit their clinical use. Expert opinion: Anti-angiogenic drugs have different profiles in terms of bioavailability, metabolism, elimination and interindividual variability in their pharmacokinetics and effectiveness. More studies should be developed to address the intrinsic and extrinsic factors influencing pharmacokinetics parameters to improve the individual therapeutic response and, furthermore, to evaluate the benefit and the harm of systemic therapy for advanced HCC in selected patients with liver impairment. |
---|---|
MeSH term(s) | Humans ; Carcinoma, Hepatocellular/drug therapy ; Carcinoma, Hepatocellular/pathology ; Angiogenesis Inhibitors ; Liver Neoplasms/drug therapy ; Liver Neoplasms/pathology ; Antineoplastic Agents/pharmacology ; Protein Kinase Inhibitors/pharmacology |
Chemical Substances | Angiogenesis Inhibitors ; Antineoplastic Agents ; Protein Kinase Inhibitors |
Language | English |
Publishing date | 2023-11-17 |
Publishing country | England |
Document type | Journal Article ; Review |
ZDB-ID | 2214462-6 |
ISSN | 1744-7607 ; 1742-5255 |
ISSN (online) | 1744-7607 |
ISSN | 1742-5255 |
DOI | 10.1080/17425255.2023.2272598 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 6264: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.